EPISODE · May 7, 2025 · 15 MIN
Munich based Ethris is developing a proprietary mRNA and lipid nanoparticle combination that is stable and allows for nasal administration or to be inhaled via nebulization
from BiotechTV - News · host BiotechTV
CEO Carsten Rudolph and CMO Thomas Langenickel describe the technology, which can be spray dried and shipped in a dry powder formulation, and also the clinical experience so far on the lead program in asthma.
What this episode covers
CEO Carsten Rudolph and CMO Thomas Langenickel describe the technology, which can be spray dried and shipped in a dry powder formulation, and also the clinical experience so far on the lead program in asthma.
NOW PLAYING
Munich based Ethris is developing a proprietary mRNA and lipid nanoparticle combination that is stable and allows for nasal administration or to be inhaled via nebulization
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m